Erectile dysfunction drugs and skin cancer — should you worry?



By health.harvard.edu

A study published in JAMA Internal Medicine in 2014 found that men who used the erection-enhancing drug sildenafil (Viagra) were 84% more likely to develop melanoma, the most dangerous form of skin cancer, over a period of 10 years.

That finding makes for an attention-grabbing headline. But it’s also what I would call a true lie: a scientifically correct statement that could easily be misunderstood to mean “that little blue pill gives you deadly skin cancer.”

Here are two truths about this work that you need to know. 1) This study does not show that Viagra causes skin cancer. Instead, it shows that in a large group of men, those who said they used Viagra ended up being diagnosed more often with melanoma than those who didn’t use this drug. The study shows a connection, not a cause. 2). Even if Viagra does promote melanoma, the absolute increase is small.

I asked an expert in melanoma and skin cancer risk at Harvard-affiliated Massachusetts General Hospital, Dr. Hensin Tsao, what he thought of the study. He kindly shot back an email offering his perspective: “This is certainly a provocative study and warrants more careful replication. Several factors need to be considered.”  Allow me to translate: The devil is in the details. The study is interesting but it does not mean that men should be worried—yet—that Viagra causes melanoma.

But they should definitely be worried about melanoma.

Risky business

The study grew out of laboratory research on how Viagra acts on cell-to-cell signaling pathways. This work demonstrated that the drug mimics key parts of a process that lets melanoma cells spread to other parts of the body. Skin cancer that spreads (metastasizes) is hard to control and can end in death.

To explore whether Viagra might have the same effect on melanoma in humans, a team of researchers looked at data collected from men taking part in the Health Professionals’ Follow-up Study, a project based at Harvard that began in 1986. The men filled out health and lifestyle questionnaires every two years. The questionnaire started asking men about use of erectile dysfunction drugs in 2000. In that year, 1,618 men reported having ever used Viagra.

Over the next decade, among the 29,929 men who said they had never used Viagra, 128 developed melanoma. Among the 1,618 Viagra users, 14 developed melanoma. In other words, 4.3 of every 1,000 who didn’t take Viagra developed melanoma compared to 8.6 of every 1,000 men who took Viagra.

After statistical adjustments, the increase from 4.3 to 8.6 is the 84% increase in risk that many news reports focused on. Researchers call that the relative risk (one group compared to another). The absolute increase, 4.3 cases per 1,000 men, represents an increase of 0.43%.

Whether a similar connection might exist between other erectile dysfunction drugs and melanoma isn’t known. In 2000, when the study was started, Viagra was the only erectile dysfunction drug on the market. Tadalafil (Cialis) and vardenafil (Levitra) weren’t approved until 2003, while avanafil (Stendra) came on the market in 2012.

How risky is that business?

The raw numbers suggest that the risk for melanoma associated with Viagra is small—one of the factors that Dr. Tsao said “need to be considered” when weighing the significance of the study. It’s even smaller than what was reported in the study because not all of the 14 cancers in the Viagra group can be attributed to the drug. Many factors affect a man’s risk of melanoma—the most important of which are age and cumulative exposure to ultraviolet (UV) radiation.

Should you worry?

Should men who use Viagra worry about getting melanoma? Right now, no one can say. The relationship could be pure coincidence. Epidemiological studies like this one tell you only who is at the scene of the crime, not who done it. The findings of the JAMA Internal Medicine study need to be replicated in other groups of men before sounding any warning bells.

In the meantime, Dr. Tsao offers some urgent advice to men: Protect your skin from too much sun and have routine skin checks to identify melanoma and other types of skin cancer early, while they are still treatable.

That’s especially important for older men, who are at greater risk for developing melanoma and also at greater risk for dying from it. An estimated 76,000 Americans (more than half of them men) will be diagnosed with melanoma this year, and almost 10,000 will die from it.

In short, be afraid—but not of Viagra. Be concerned about getting too much sun and pay attention to weird-looking moles that could turn into metastatic cancer. Cover up when you go outside, and use a broad-spectrum sunscreen liberally when you do go out into the sun to work and play.

Source: http://www.health.harvard.edu/blog/erectile-dysfunction-drugs-skin-cancer-worry-201406057197

what insurance covers cialis http://cialissom.com/ cialis und zeugungsfähigkeit cialis cheap cialis kaiser permanente cialis cheap differenza tra levitra e cialis http://cialisles.com/ sklep z cialis

Thursday, May 28, 2026

HPV Vaccine: Protection Against Cancer-Causing Virus

Human papillomavirus is the most common sexually transmitted infection in the United States. While most HPV infections clear on their own without causing problems, persistent infection with certain high-risk strains causes most cases of cervical cancer and contributes to cancers of the oropharynx, anus, penis, vagina, and vulva. The HPV vaccine is one of the most powerful cancer prevention tools available, and vaccination before exposure provides the greatest benefit. Currently available HPV vaccines protect against the strains most commonly associated with cancer and genital warts. The 9-valent vaccine Gardasil 9 protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. Types 16 and 18 are responsible for approximately 70 percent of cervical cancers. Types 6 and 11 cause 90 percent of genital warts. Broad coverage against multiple high-risk and low-risk strains maximizes protection. The HPV vaccine is recommended as a routine vaccine for all adolescents at age 11 or 12, with a two-dose schedule when started before age 15. Three doses are given when vaccination starts at age 15 or older. Vaccination is recommended through age 26 for anyone not previously vaccinated. Adults aged 27 to 45 may benefit from vaccination after discussion with their healthcare provider, though the benefit declines with increasing prior exposure to HPV. For health needs related to sexually transmitted infections and associated treatments, care is accessible through https://www.amoxilcompharm.com/. The HPV vaccine is safe and highly effective. Clinical trials demonstrated nearly 100 percent efficacy against the specific HPV types covered by the vaccine in individuals who had not previously been exposed. The vaccines do not contain live virus and cannot cause HPV infection. Common side effects are mild and include injection site soreness, dizziness, and low-grade fever. Even vaccinated individuals should continue recommended cervical cancer screening with Pap smears and HPV tests, as the vaccine does not protect against all cancer-causing HPV types and does not clear pre-existing infections. For comprehensive HPV vaccine information and preventive health resources, visit https://amoxicillina.online/ for evidence-based patient guidance.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)